{"id":"aav2haqp1","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AAV2 vector delivers the hAQP1 gene to the retina to treat Leber congenital amaurosis 10 (LCA10)","oneSentence":"AAV2-mediated gene therapy targeting aquaporin-1","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:51:21.431Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Leber congenital amaurosis 10 (LCA10)"}]},"trialDetails":[{"nctId":"NCT02446249","phase":"PHASE1","title":"Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction","status":"ACTIVE_NOT_RECRUITING","sponsor":"MeiraGTx, LLC","startDate":"2015-05-04","conditions":"Squamous Cell Head and Neck Cancer, Radiation Induced Xerostomia, Salivary Hypofunction","enrollment":17},{"nctId":"NCT05060341","phase":"","title":"Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia","status":"ACTIVE_NOT_RECRUITING","sponsor":"MeiraGTx, LLC","startDate":"2020-11-12","conditions":"Radiation-induced Xerostomia","enrollment":22},{"nctId":"NCT04043104","phase":"PHASE1","title":"A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and Xerostomia","status":"COMPLETED","sponsor":"MeiraGTx UK II Ltd","startDate":"2019-06-30","conditions":"Radiation-Induced Parotid Gland Hypofunction, Xerostomia Due to Radiotherapy, Head and Neck Cancer","enrollment":24},{"nctId":"NCT00372320","phase":"PHASE1","title":"Effect of AdhAQP1 on Salivary Flow in Patients Treated With Radiation for Head and Neck Cancer","status":"COMPLETED","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2006-09-01","conditions":"Parotid Salivary Dysfunction","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AAV2hAQP1","genericName":"AAV2hAQP1","companyName":"MeiraGTx, LLC","companyId":"meiragtx-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"AAV2-mediated gene therapy targeting aquaporin-1 Used for Leber congenital amaurosis 10 (LCA10).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}